What did the studies actually find?
You see a weight-loss claim in a search result. You want to know what was measured, and what the claim leaves out.
A study result describes a group in a particular setting. Read the comparison and the limits beside the result.
Weight loss in a named trial
Over 72 weeks in SURMOUNT-1, adults without diabetes had average weight loss of roughly 15%–21% on tirzepatide.
The amount varied across the trial’s treatment groups.
The group on placebo, a dummy treatment used for comparison, lost about 3%.
The drug maker supported this trial. Participants had regular visits, along with help to change their eating and activity habits.
An average cannot tell you what will happen to you. Ask how those study conditions compare with the care being offered.
What happened after treatment was withdrawn
In SURMOUNT-4, people first had tirzepatide for 36 weeks, then continued it or switched to a dummy treatment for another 52 weeks.
The study measured the next changes from each person’s weight on the day treatment changed. Over the next 52 weeks, the dummy-treatment group gained about 14% of that weight. The group continuing tirzepatide lost about 5.5% of that weight.
The 14% is a share of their whole weight on the day of the switch. It is not a share of the weight they had already lost.
This is a reason to ask what stopping might mean for you. It does not decide how long your treatment will last.
A reading list, with a reason to open each source
SURMOUNT-1: the weight trial
The journal summary reports the weight changes and the placebo comparison. It studies selected adults without diabetes, not every person seeking care.
SURMOUNT-4: continuing or stopping
This study addresses weight after a switch to placebo. The people in that phase had already completed the initial treatment period.
Cochrane’s review of the trials
Cochrane’s reviewers looked at the studies together to judge what they showed. Its reviewers flagged that the included trials were paid for by the drug maker.
Zepbound’s product label
The Food and Drug Administration (FDA) label sets out uses and cautions for Zepbound (tirzepatide). Results for the approved product do not establish equal results for a compounded preparation.
Medical-board guidance on care
Doctors’ licensing boards form the membership of the Federation of State Medical Boards, whose guidance explains why health checks and questions matter. Its advice helps boards set care rules. Each state decides the rules a prescriber must follow.